A Phase 2b Study of DIO-902 or DIO-902 Placebo in Addition to Metformin and Atorvastatin or Atorvastatin Placebo for Type 2 Diabetes

PHASE2TerminatedINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

July 31, 2007

Primary Completion Date

March 31, 2008

Study Completion Date

December 31, 2008

Conditions
Type 2 Diabetes
Interventions
DRUG

DIO-902

150mg tablet once per day for 16 weeks

DRUG

DIO-902

300mg tablet once per day for 16 weeks

DRUG

DIO-902

450mg DIO-902 tablet once daily for 16 weeks

DRUG

DIO-902 placebo

DIO-902 placebo tablet once daily for 16 weeks

DRUG

DIO-902

150mg tablet of DIO-902 once daily for 16 weeks

DRUG

DIO-902

300mg DIO-902 tablet daily for 16 weeks

DRUG

DIO-902

450mg DIO-902 tablet for 16 weeks

DRUG

DIO-902 placebo

DIO-902 placebo tablet once daily for 16 weeks

Trial Locations (24)

6009

Keough Institute, Nedands

6160

School of Medicine and Pharmacology, Fremantle

35662

Dr. Terence Hart, Muscle Shoals

68131

Creighton Diabetes Center, Omaha

72211

Arkansas Primary Care Clinic, Little Rock

72401

Research Solutions, Jonesboro

74104

AHS Oklahoma Physician Group, Tulsa

78229

Diabetes Glandular and Disease Research Associates, San Antonio

78752

Covance CRU, Austin

85741

Genova Research, Tucson

90712

Advanced Medical Research, Lakewood

94401

Mills-Peninsula Helath Services, San Mateo

96813

Diabetes Research Goup University of Hawaii at Manoa, Honolulu

927239

Covance Clinical Research Unit - Dr. Andrew Ahmann, Portland

Unknown

Flinders Medical Centre, Adelaide

Lyell McEwin Hospital, North Western Adelaide

ECRU, Box Hill, Melbourne

Royal Melbourn Hospital, Victoria

Middlemore Hospital, Otahuhu

Lipid and Diabetes Research, Christchurch

Waikaito Hospital, Hamilton

Diabetes Centre, Wellington

QLD 4029

Endocrinology Research Unit, Herston Road

NSW 2065

Endocrinology Department, St Leonards

Sponsors

Lead Sponsor

All Listed Sponsors
lead

DiObex

INDUSTRY